JP2610784B2 - フェノールアルカノールアミノ誘導体 - Google Patents

フェノールアルカノールアミノ誘導体

Info

Publication number
JP2610784B2
JP2610784B2 JP6205530A JP20553094A JP2610784B2 JP 2610784 B2 JP2610784 B2 JP 2610784B2 JP 6205530 A JP6205530 A JP 6205530A JP 20553094 A JP20553094 A JP 20553094A JP 2610784 B2 JP2610784 B2 JP 2610784B2
Authority
JP
Japan
Prior art keywords
formula
compound
methyl
phenylmethyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP6205530A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0782250A (ja
Inventor
エルノ・モハクスル
ジェー・フィリップ・オブライエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JPH0782250A publication Critical patent/JPH0782250A/ja
Application granted granted Critical
Publication of JP2610784B2 publication Critical patent/JP2610784B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
  • Table Devices Or Equipment (AREA)
  • Fats And Perfumes (AREA)
  • Organic Insulating Materials (AREA)
JP6205530A 1993-09-02 1994-08-30 フェノールアルカノールアミノ誘導体 Expired - Fee Related JP2610784B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11638593A 1993-09-02 1993-09-02
US08/116385 1993-09-02

Publications (2)

Publication Number Publication Date
JPH0782250A JPH0782250A (ja) 1995-03-28
JP2610784B2 true JP2610784B2 (ja) 1997-05-14

Family

ID=22366865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6205530A Expired - Fee Related JP2610784B2 (ja) 1993-09-02 1994-08-30 フェノールアルカノールアミノ誘導体

Country Status (22)

Country Link
EP (1) EP0648744B1 (enExample)
JP (1) JP2610784B2 (enExample)
KR (1) KR100360954B1 (enExample)
CN (1) CN1061035C (enExample)
AT (1) ATE162520T1 (enExample)
AU (1) AU7149794A (enExample)
BR (1) BR9403418A (enExample)
CA (1) CA2129771C (enExample)
CZ (1) CZ210694A3 (enExample)
DE (1) DE69408078T2 (enExample)
DK (1) DK0648744T3 (enExample)
ES (1) ES2113585T3 (enExample)
FI (1) FI107607B (enExample)
GR (1) GR3026622T3 (enExample)
HU (1) HUT70558A (enExample)
IL (1) IL110812A0 (enExample)
NO (1) NO943231L (enExample)
NZ (1) NZ264320A (enExample)
PL (1) PL304863A1 (enExample)
RU (1) RU94031753A (enExample)
TW (1) TW281670B (enExample)
ZA (1) ZA946529B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658909A (en) * 1994-11-17 1997-08-19 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease
US6214994B1 (en) 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
US5693804A (en) * 1994-11-17 1997-12-02 Molecular Geriatrics Corporation Substituted 1-aryl-3-piperazin-1'-yl propanones
FR2742051B1 (fr) * 1995-12-06 1998-02-06 Synthelabo Utilisation de composes ayant une affinite pour le site de liaison du (3h)ifenprodil pour la fabrication de medicaments utiles dans la prevention et le traitement des neuropathies
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
PL340080A1 (en) 1997-10-24 2001-01-15 Warner Lambert Co Method of treating disease-related or post-drug dyskinesias
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
DE19812331A1 (de) * 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
DE60228969D1 (enExample) * 2001-07-24 2008-10-30 Richter Gedeon Nyrt
EP1666464A4 (en) 2003-09-25 2008-12-10 Shionogi & Co PIPERIDINE DERIVATIVE HAVING ANTAGONIST ACTIVITY OF THE NDMA RECEPTOR
KR20140097132A (ko) 2011-11-22 2014-08-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 허혈성 손상을 치료하기 위한 시스테아민 및/또는 시스타민
RU2649406C1 (ru) * 2017-09-21 2018-04-03 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 3-n-замещенные борнилпропионаты, используемые в качестве ингибиторов вируса марбург

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4261285A (en) * 1984-06-01 1985-12-05 Tokyo Tanabe Company Limited 1-propanone derivatives
DE3433036A1 (de) * 1984-09-08 1986-03-20 Basf Ag, 6700 Ludwigshafen Piperidinderivate und diese enthaltende fungizide sowie verfahren zur bekaempfung von pilzen
ES2098248T3 (es) * 1989-05-17 1997-05-01 Pfizer Derivados de 2-piperidino-1-alcanoles como agentes antiisquemicos.
US4940789A (en) * 1989-10-10 1990-07-10 American Home Products Corporation 10,11-dihydro-5-alkyl-12-substituted-10,5-(iminomethano)-5H-dibenzo[a,d]cycloheptenes as neuroprotectant agents
WO1992006957A1 (en) * 1990-10-15 1992-04-30 Fisons Corporation 2-phenyl-and 2-thienyl-(2)-piperidine derivatives having neuroprotective properties
SE9003652D0 (sv) * 1990-11-15 1990-11-15 Astra Ab New heterocyclic compounds

Also Published As

Publication number Publication date
DE69408078D1 (de) 1998-02-26
FI944044A0 (fi) 1994-09-02
HUT70558A (en) 1995-10-30
CN1061035C (zh) 2001-01-24
DK0648744T3 (da) 1998-09-21
AU7149794A (en) 1995-03-16
JPH0782250A (ja) 1995-03-28
CA2129771C (en) 2006-03-21
KR100360954B1 (ko) 2003-04-16
IL110812A0 (en) 1994-11-11
NO943231L (no) 1995-03-03
DE69408078T2 (de) 1998-07-09
GR3026622T3 (en) 1998-07-31
FI944044L (fi) 1995-03-03
NO943231D0 (no) 1994-09-01
ATE162520T1 (de) 1998-02-15
ZA946529B (en) 1995-03-02
CZ210694A3 (en) 1995-08-16
CN1105990A (zh) 1995-08-02
TW281670B (enExample) 1996-07-21
EP0648744A1 (en) 1995-04-19
RU94031753A (ru) 1996-07-20
CA2129771A1 (en) 1995-03-03
HU9402479D0 (en) 1994-10-28
NZ264320A (en) 1996-02-27
PL304863A1 (en) 1995-03-06
FI107607B (fi) 2001-09-14
ES2113585T3 (es) 1998-05-01
KR950008481A (ko) 1995-04-17
BR9403418A (pt) 1996-09-03
EP0648744B1 (en) 1998-01-21

Similar Documents

Publication Publication Date Title
JP2610784B2 (ja) フェノールアルカノールアミノ誘導体
NO180445B (no) 2-(4-hydroksypiperidino)-1-alkanol-derivater som anti-iskemiske midler
AU2001273942A1 (en) Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders
EP1278728A1 (en) Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders
HUT77520A (hu) Neuroprotektív hatású kromán-4,7-diol- és 1-(4-hidroxifenil)-alkanol-származékok és azokat hatóanyagként tartalmazó gyógyszerkészítmények
EP0030526B1 (en) New phenyl-azacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds
EP0674514A1 (en) Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives
JP4937347B2 (ja) 置換フェニルメタノン誘導体
TW299231B (enExample)
AU638173B2 (en) 1-(3,4-dihydro-2-oxo-1h-quinolin-6-y1)-2-{4-(2-phenylethyl) piperidin-1-y1}ethanol and -ethanone, their preparation and their therapeutic application
AU769284B2 (en) Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof
EA017631B1 (ru) Кристаллическое основание транс-1-((1r,3s)-3-фенил-6-хлороиндан-1-ил)-3,3-диметилпиперазина
US7067535B2 (en) 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis
US4719219A (en) Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders
JP3615496B2 (ja) １−（４−ヒドロキシフェニル）−２−（４−ヒドロキシ−４−フェニルピペリジン−１−イル）−１−プロパノールのメシレート塩・３水和物を製造するための方法
KR100432841B1 (ko) 1-(4-히드록시페닐)-2-(4-히드록시-4-페닐피페리딘-1-일)-1-프로판올의 메실레이트염 삼수화물의 제조 방법 및 이에유용한 중간체
AU4453799A (en) The use of aryl-cyclohexylamine derivatives against CNS disorders
JP2008527016A (ja) 神経及び神経精神病の疾患の治療のためのグリシントランスポーター１（ＧｌｙＴ−１）阻害剤としての２，５−二置換フェニルメタノン誘導体
US4937346A (en) Phenyl-azacykloalkanes
MXPA99007589A (en) Use of aril-ciclohexilamine derivatives against disorders of the central nervous system
AU2003268868A1 (en) Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees